Eosinophilic Cationic Protein as a Biomarker in Diagnosis of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
NCT ID: NCT04008017
Last Updated: 2021-04-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
64 participants
OBSERVATIONAL
2019-08-01
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Inflammation is a core feature of acute exacerbation of Chronic obstructive pulmonary disease since it gives insight into the pathological changes causing an exacerbation. Eosinophils may play a significant role in airway inflammation in some patients with Chronic obstructive pulmonary disease.
Previous studies have indicated that eosinophilic airway inflammation is also associated with the development of severe acute exacerbation of Chronic obstructive pulmonary disease. Eosinophilic Cationic Protein has various biological activities, including antibacterial, antiviral, antiparasitic and neurotoxic functions, and it contributes to the regulation of fibroblast activity. Eosinophilic Cationic Protein also induces airway mucus secretion and interacts with the coagulation and complement systems. Eosinophilic Cationic Protein has been developed as a marker for eosinophilic disease and quantified in biological fluids including serum, bronchoalveolar lavage and nasal secretions. It is found in diseases such as allergic asthma and allergic rhinitis but also occasionally in other diseases. Only activated eosinophil granulocytes release the granule content and therefore the determination of Eosinophilic Cationic Protein concentration is a considerably more specific indicator of eosinophil inflammation than eosinophil granulocyte count in peripheral blood as serum Eosinophilic Cationic Protein levels increase during acute exacerbation of Chronic obstructive pulmonary disease
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exhaled Breath Condensate (EBC) Assessment in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
NCT00448500
Diagnostic Values of C-reactive Protein and Procalcitonin in Predicting Bacterial Infection in Acute Exacerbations of Chronic Obstructive Pulmonary Disease
NCT03923803
CRP, Procalcitonin and Pro-BNP as Diagnostic and Prognostic Markers in AECOPD
NCT06514599
Bronchial Asthma & Its Exacerbation
NCT06331897
A Study to Evaluate Biomarkers in Chronic Obstructive Pulmonary Disease
NCT01268072
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
stable Chronic obstructive pulmonary disease
clinical features of Chronic obstructive pulmonary disease and associated spirometry compatible with the GOLD criteria (Forced expiratory volume 1/ Forced vital capacity \<70%) post bronchodilator
Eosinophilic Cationic Protein biomarker
3 ml blood for serum sample for estimation of Eosinophilic Cationic Protein biomarker level using ELISA
acute exacerbation of Chronic obstructive pulmonary disease
patients developed fever, increased dyspnea and sputum production plus the clinical features of Chronic obstructive pulmonary disease and associated spirometry compatible with the GOLD criteria (Forced expiratory volume 1/ Forced vital capacity \<70%) post bronchodilator
Eosinophilic Cationic Protein biomarker
3 ml blood for serum sample for estimation of Eosinophilic Cationic Protein biomarker level using ELISA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Eosinophilic Cationic Protein biomarker
3 ml blood for serum sample for estimation of Eosinophilic Cationic Protein biomarker level using ELISA
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* spirometry compatible with the GOLD criteria (Forced expiratory volume 1/ Forced vital capacity \<70%) post bronchodilator.
Exclusion Criteria
* Asthma -Chronic obstructive pulmonary disease overlap syndrome
* Atopic patients
* Pneumothorax
* Congestive heart failure
* Cancer of any kind
* A history of major surgery in the preceding 4 weeks.
* Patients undergoing mechanical ventilation or presenting with azotaemia (serum creatinine \>1.5 mg/dl).
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Mohamed Abbas
Principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assiut Faculty of Medicine
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COPD-ECP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.